drugset / Trial / NCT02223481

Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension

NCT02223481

Phase 2 Completed 71 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

This study sought to determine whether terbogrel was an effective treatment for primary pulmonary hypertension (PPH) by comparing its efficacy and safety to that of placebo.

Timeline

Start
1998-05
Primary completion
1999-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbogrel Small molecule